Canada markets closed

Titan Medical Inc. (TMDIF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0440+0.0032 (+7.84%)
At close: 03:41PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0408
Open0.0420
BidN/A x N/A
AskN/A x N/A
Day's Range0.0392 - 0.0488
52 Week Range0.0392 - 0.1900
Volume70,715
Avg. Volume113,450
Market Cap5.018M
Beta (5Y Monthly)1.98
PE Ratio (TTM)0.73
EPS (TTM)0.0600
Earnings DateJun 07, 2024 - Jun 11, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Titan Provides Update on Planned Merger with Conavi

    TORONTO, Ontario, April 22, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to provide this update on its planned merger with Conavi Medical Inc. (“Conavi”) as previously announced on March 18, 2024 (the “Transaction”). As previously announced, Titan has entered into a definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 with Conavi Medical Inc. (“Conavi”) providing for the combination of the companies in an all-stock trans

  • GlobeNewswire

    Titan Settles Contractual Dispute with Contract Manufacturer

    TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that it has entered into a settlement agreement with a contract manufacturer (“Contractor”). Titan has reached a settlement agreement in connection with a dispute with the Contractor. Under the terms of the settlement, Titan has agreed to pay the Contractor an aggregate of US$2 million, with the final payment installment to be made on or before June 24, 2024. Upon receipt of the ful

  • GlobeNewswire

    Titan Medical Reports Fiscal Year 2023 Results

    TORONTO, Ontario, March 29, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), today reported financial results for the fiscal year ended December 31, 2023. Recent Activities: On August 14, 2023, the Company announced the appointment of Dr. Daniel O’Brien, MD, MBA, Ph.D to its Board of Directors.On August 21, 2023, the Company announced a licensing agreement with Auris Health, Inc., a Johnson & Johnson MedTech Company.On October 18, 2023, the Company a